Clarus — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.
BiotechHealthtechSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)Thomas Wiggans(Director)Ricky Sun(Director)
Board seatEmmett Cunningham· per SEC Form D · $85M raise · filed Dec 2018
Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsSV Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.